TL;DR: Aetna, a CVS Health company, modified CPB 0860 for critical flicker fusion, effective January 5, 2026. The policy classifies critical flicker fusion as experimental, investigational, or unproven across all listed indications — meaning no covered reimbursement path exists for this test under Aetna plans.
Critical flicker fusion billing just got a hard wall. Aetna's updated CPB 0860 critical flicker fusion coverage policy makes the payer's position explicit: this test does not meet medical necessity standards for any of the six clinical scenarios spelled out in the bulletin. If your practice has been billing for this procedure in ophthalmology, hepatology, or neurology workflows, you need to review those claims now. The policy lists CPT 65770 (keratoprosthesis) and the full cataract surgery code range — CPT 66820 through 66899 — as related codes, which tells you exactly where Aetna expects billing teams to pay attention.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Critical Flicker Fusion — CPB 0860 |
| Policy Code | CPB 0860 |
| Change Type | Modified |
| Effective Date | January 5, 2026 |
| Impact Level | Medium — focused on ophthalmology, hepatology, and neurology practices that use CFF testing as a diagnostic adjunct |
| Specialties Affected | Ophthalmology, hepatology, neurology, pharmacology/clinical research billing |
| Key Action | Audit any claims pairing critical flicker fusion testing with cataract surgery (CPT 66820–66899) or keratoprosthesis (CPT 65770) and remove or justify before submitting to Aetna |
Aetna Critical Flicker Fusion Coverage Criteria and Medical Necessity Requirements 2026
The short answer: there are no covered indications under this policy. Aetna's CPB 0860 Aetna system classification treats critical flicker fusion as experimental, investigational, or unproven across the board. The policy does not carve out any scenario where medical necessity can be established for this test.
That matters because "experimental, investigational, or unproven" is the hardest classification to appeal. It's not a prior authorization problem you can solve with better documentation. It's not a coverage policy gap you can bridge with a letter of medical necessity from the ordering physician. Aetna is saying the clinical evidence doesn't support this test — full stop.
If your compliance officer or billing consultant has told you this is an edge case, revisit that conversation with the January 5, 2026 effective date in hand. This modification makes the policy current and explicit for 2026.
Aetna Critical Flicker Fusion Exclusions and Non-Covered Indications
Aetna lists six specific clinical indications as experimental under CPB 0860. None qualify for reimbursement.
Here's what the policy names directly:
1. Neurotoxicity monitoring and visual fatigue in pharmacology
Using critical flicker fusion as an indicator of neurotoxic drug adverse events or visual fatigue does not meet Aetna's medical necessity standard. This affects clinical pharmacology and research-adjacent billing.
2. Diagnosis of minimal hepatic encephalopathy
Critical flicker fusion has been studied as a low-cost screening tool for low-grade hepatic encephalopathy. Aetna does not accept that evidence base. Hepatology practices that have incorporated this test into their encephalopathy workup need to stop billing it to Aetna patients.
3. Diagnosis of visual acuity
Using CFF testing as a proxy or adjunct for visual acuity measurement is not covered. Standard visual acuity assessment codes remain the appropriate path.
4. Differential diagnosis of demyelinating optic neuritis vs. ischemic optic neuropathy
This is a scenario where CFF has some clinical literature support — but not enough to clear Aetna's threshold. Neuro-ophthalmology practices billing this indication to Aetna will face claim denial.
5. Prediction of executive dysfunction
Neuropsychological applications don't have an approved path here either.
6. Predicting visual outcomes in keratoprosthesis or cataract/macular surgery
This is the indication most directly tied to the CPT codes in this policy — CPT 65770 for keratoprosthesis and CPT 66820–66899 for cataract surgery. The idea is that CFF testing could help predict post-surgical visual outcomes. Aetna says the evidence doesn't support it.
Coverage Indications at a Glance
| Indication | Coverage Status | Relevant Codes | Notes |
|---|---|---|---|
| Neurotoxic drug adverse event monitoring / visual fatigue | Not Covered (Experimental) | — | No approved billing path under Aetna |
| Diagnosis of minimal hepatic encephalopathy | Not Covered (Experimental) | — | Affects hepatology practices using CFF as encephalopathy screen |
| Visual acuity diagnosis | Not Covered (Experimental) | — | Use standard visual acuity assessment codes instead |
| Differential diagnosis: demyelinating optic neuritis vs. ischemic optic neuropathy | Not Covered (Experimental) | — | Despite clinical literature, Aetna does not accept the evidence base |
| Prediction of executive dysfunction | Not Covered (Experimental) | — | Neuropsychology applications not covered |
| Predicting visual outcomes in keratoprosthesis surgery | Not Covered (Experimental) | CPT 65770 | Bundled pre-surgical testing not reimbursable |
| Predicting visual outcomes in cataract or macular disease surgery | Not Covered (Experimental) | CPT 66820–66899 | Entire cataract code range flagged as related to this CPB |
Aetna Critical Flicker Fusion Billing Guidelines and Action Items 2026
The policy is clear. Your action items should match that clarity.
| # | Action Item |
|---|---|
| 1 | Audit open claims before January 5, 2026 becomes your problem retroactively. Pull any claims you've submitted to Aetna that include critical flicker fusion testing alongside CPT 65770 or any cataract surgery code in the 66820–66899 range. Flag them for review now. |
| 2 | Remove critical flicker fusion from your pre-surgical testing protocols for Aetna patients. If your ophthalmology or surgical team uses CFF as part of a pre-op visual outcome prediction workup, that protocol needs a payer carve-out for Aetna members. The test itself isn't the problem — billing it to Aetna is. |
| 3 | Update your charge capture templates. If CFF testing appears as a default or optional line item in any charge capture workflow tied to cataract surgery, keratoprosthesis, or hepatic encephalopathy evaluation, pull it out of the Aetna-specific version. |
| 4 | Educate your hepatology billing team directly. The minimal hepatic encephalopathy indication surprises people. Some hepatology practices adopted CFF testing because it's inexpensive and non-invasive. That clinical rationale doesn't translate to Aetna reimbursement — and hasn't as of this effective date. |
| 5 | Do not pursue prior authorization as a workaround. Prior authorization exists to confirm medical necessity before service. When a payer classifies something as experimental, prior auth doesn't apply — there's nothing to authorize. If your team has been requesting prior auth for CFF testing with Aetna, stop. It won't produce a covered claim. |
| 6 | If you're billing CFF for neuro-ophthalmology cases — optic neuritis vs. ischemic optic neuropathy differentiation — talk to your compliance officer. This is a nuanced clinical area with real diagnostic value. But Aetna's position is firm. Your compliance officer needs to know this exposure exists before you submit another claim. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Critical Flicker Fusion Under CPB 0860
This policy does not designate any CPT codes as covered for critical flicker fusion. Every code listed in CPB 0860 is classified as "related to the CPB" — meaning Aetna flags them as the surgical or procedural context where CFF testing is likely to appear and be inappropriately billed.
HCPCS Codes
The policy lists two HCPCS codes but does not provide descriptions in the available data. Check the full CPB 0860 document on Aetna's portal or via PayerPolicy for the complete HCPCS detail.
Key Diagnostic Context — ICD-10-CM
The policy references 125 ICD-10-CM codes. These span hepatic encephalopathy diagnoses, visual system disorders (optic neuritis, ischemic optic neuropathy), cataract diagnoses, and neurological conditions. The ICD-10 codes tell you what diagnosis codes Aetna expects to see on claims where CFF billing might be attempted — and where they'll be watching for denials. The full code list is available in the source policy document.
A Note on the Scope of This Coverage Policy
The code range here deserves a second look. A coverage policy that spans the full cataract surgery CPT range — 80 codes across CPT 66820–66899 — is signaling something specific. Aetna isn't just addressing a niche diagnostic test. They're drawing a clear line around the entire pre-surgical and surgical ophthalmology workflow. CFF testing does not belong in that billing chain for Aetna patients.
That's a practical statement about how claims get reviewed. If Aetna's claims system sees CPT 65770 or any cataract code alongside a CFF-related charge, that claim is a denial candidate. The billing guidelines here aren't complicated — they just require your team to act before you submit, not after.
Get the Full Picture for CPT 65770
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.